ライフサイエンスコーパス: pyogenes

1 l species, SaCas9 (S. aureus) and SpCas9 (S. pyogenes).

2 from Staphylococcus aureus and Streptococcus pyogenes.

3 d by Staphylococcus aureus and Streptococcus pyogenes.

4 ely, Staphylococcus aureus and Streptococcus pyogenes.

5 with the riboflavin auxotroph Streptococcus pyogenes.

6 n cells and kill intracellular Streptococcus pyogenes.

7 and the function of VNTR polymorphisms in S. pyogenes.

8 el factors related to the invasiveness of S. pyogenes.

9 in response to infection with Streptococcus pyogenes.

10 tide from the mucosal pathogen Streptococcus pyogenes.

11 on proteins from the bacterium Streptococcus pyogenes.

12 situation after infection with Streptococcus pyogenes.

13 ributes to the immune evasion strategy of S. pyogenes.

14 43.5%] vs 4 [12.9%]; P = .02), Streptococcus pyogenes (2 [8.7%] vs 19 [61.3%]; P < .001) and Escheric

15 N-beta, which is significantly induced by S. pyogenes 23S rRNA in an Irf5-dependent manner.

16 from Staphylococcus aureus and Streptococcus pyogenes(5,7).

17 In Streptococcus pyogenes, a common and potentially deadly pathogen, many

18 Streptococcus pyogenes, a human-restricted pathogen, accounts for subs

19 Streptococcus pyogenes activates IFN-I production in innate immune cel

20 strated that the released M1 protein from S. pyogenes activates platelets, and this activation is dep

21 eA production has emerged during increased S pyogenes activity in England.

22 Here, we report that Streptococcus pyogenes also hijack lymphatic vessels to escape a local

23 result for samples containing Streptococcus pyogenes and a negative result for those without.

24 hat is essential for growth of Streptococcus pyogenes and contributes to its ability to infect the hu

25 ed an RNase III null mutant of Streptococcus pyogenes and its RNA sequencing (RNA-Seq) data were anal

26 hal soft tissue infection with Streptococcus pyogenes and prevented bacterial dissemination.

27 inst Staphylococcus aureus and Streptococcus pyogenes and protected against staphylococcal alpha-toxi

28 iagnose include Staphylococci, Streptococcus pyogenes and Pseudomonas aeruginosa in blepharitis; Stap

29 Finally, we assess comparative S. pyogenes and S. aureus Cas9 specificity using GUIDE-seq.

30 Both Streptococcus pyogenes and Streptococcus pneumoniae are widely thought

31 ompared to the closely related Streptococcus pyogenes and Streptococcus pneumoniae, and while researc

32 common human pathogens, e.g., Streptococcus pyogenes and Streptococcus pneumoniae.

33 combine the CRISPR system from Streptococcus pyogenes and synthetic antisense RNAs (asRNAs) in Escher

34 of patients with GP respond to Streptococcus pyogenes and whether this initial immune response is fav

35 ive (Staphylococcus aureus and Streptococcus pyogenes) and gram-negative bacteria (Pseudomonas aerugi

36 Moraxella catarrhalis, S. pyogenes, and culture-negative episodes were also signif

37 (NTHi), Moraxella catarrhalis, Streptococcus pyogenes, and culture-negative OM.

38 he significant human pathogen, Streptococcus pyogenes, and proteins from human saliva and plasma obta

39 from Staphylococcus aureus and Streptococcus pyogenes, and recombinant Cas9 and developed protocols f

40 Streptococcus pyogenes, and to a lesser extent, Staphylococcus aureus,

41 report the development of the Streptococcus pyogenes anti-CRISPR/Cas9 protein, AcrIIA4, as a novel a

42 h as Staphylococcus aureus and Streptococcus pyogenes, are the dominant organisms isolated early in t

43 on the tip of the T3 pilus of Streptococcus pyogenes as a fusion to the Cpa protein (LL-Gag).

44 pathogen the group A Streptococcus (GAS; S. pyogenes) as a model organism, we review the types and r

45 ctor SpeB and to the overall virulence of S. pyogenes, as both DacA and Pde2 null mutants were highly

46 e FIC of >2.5 mM, while those of Bacteroides pyogenes, B. fragilis, and Akkermansia muciniphila were

47 allenged by HRG, sHIP was found to rescue S. pyogenes bacteria.

48 lated by neonatal exposure to heat-killed S. pyogenes bacteria.

49 ansgenic mouse model expressing human FH (S. pyogenes binds FH in a human-specific manner).

50 lls prevented nasopharyngeal infection by S. pyogenes, but not by Streptococcus pneumoniae, a bacteri

51 r, these data show that ME contributes to S. pyogenes' carbon source repertory, that malate utilizati

52 ing modules, the nuclease-dead Streptococcus pyogenes Cas9 (dCas9) protein, which recognizes a specif

53 Although the widely used Streptococcus pyogenes Cas9 (SpCas9) and its engineered variants have

54 The targeting scope of Streptococcus pyogenes Cas9 (SpCas9) and its engineered variants is la

55 get effects of the widely used Streptococcus pyogenes Cas9 (SpCas9) are imperfect, possessing only pa

56 we show that the commonly used Streptococcus pyogenes Cas9 (SpCas9) can be modified to recognize alte

57 The success of Streptococcus pyogenes Cas9 (SpCas9) has led to the discovery of sever

58 Here we detect antibodies to Streptococcus pyogenes Cas9 (SpCas9) in at least 5% of 143 healthy ind

59 tion in TCAP, treated with the Streptococcus pyogenes Cas9 (SpCas9) nuclease revealed that about 80%

60 -cassette system expressing pieces of the S. pyogenes Cas9 (SpCas9) protein which splice together in

61 c small-molecule inhibitors of Streptococcus pyogenes Cas9 (SpCas9) that weigh <500 Da and are cell p

62 int, we engineered variants of Streptococcus pyogenes Cas9 (SpCas9) to eliminate the NGG PAM requirem

63 et al. structurally engineered Streptococcus pyogenes Cas9 (SpCas9) to near-PAMless SpRY that can tar

64 Streptococcus pyogenes Cas9 (SpCas9), a CRISPR-associated protein, has

65 ly used endonucleases, such as Streptococcus pyogenes Cas9 (SpCas9), can tolerate up to seven mismatc

66 is significantly smaller than Streptococcus pyogenes Cas9 (SpCas9), to facilitate efficient in vivo

67 ncy as previously reported for Streptococcus pyogenes Cas9 (SpCas9).

68 with those of the widely used Streptococcus pyogenes Cas9 (SpCas9).

69 to improve the specificity of Streptococcus pyogenes Cas9 (SpCas9).

70 ide RNAs (sgRNAs) for use with Streptococcus pyogenes Cas9 (SpCas9).

71 yond the 44 degrees C limit of Streptococcus pyogenes Cas9 (SpyCas9) and the 70 degrees C limit of bo

72 fecal metagenomes that inhibit Streptococcus pyogenes Cas9 (SpyCas9) in Escherichia coli.

73 ly used genome editing protein Streptococcus pyogenes Cas9 (SpyCas9), we used both self-targeting CRI

74 , compared to 45 degrees C for Streptococcus pyogenes Cas9 (SpyCas9), which expands the temperature r

75 (SinCas9) and weakly inhibits Streptococcus pyogenes Cas9 (SpyCas9).

76 Structures of Streptococcus pyogenes Cas9 alone or bound to single-guide RNA (sgRNA)

77 stem leverages the programmability of the S. pyogenes Cas9 and is based on flexible arrangements of i

78 with mutually permissive NGGRRT PAMs, the S. pyogenes Cas9 and S. aureus Cas9 yield indels at compara

79 successfully delivered a plasmid encoding S. pyogenes Cas9 and sgRNA to the corneal epithelium by int

80 at are also among the smallest Streptococcus pyogenes Cas9 base editors described to date.

81 Streptococcus pyogenes Cas9 cleavage of the viral genome requires the

82 At low forces, the Streptococcus pyogenes Cas9 complex binds and cleaves DNA specifically

83 he sugar-phosphate backbone of Streptococcus pyogenes Cas9 CRISPR RNA (crRNA) to probe chemical and s

84 pressing maize codon-optimized Streptococcus pyogenes Cas9 endonuclease and single guide RNAs were co

85 eport the crystal structure of Streptococcus pyogenes Cas9 in complex with sgRNA and its target DNA a

86 Confirmation that S. pyogenes Cas9 lacks the specificity to discriminate betw

87 tgRNA) that repeatedly directs Streptococcus pyogenes Cas9 nuclease activity toward the DNA that enco

88 de preferences at the seventh position of S. pyogenes Cas9 PAM (5'-NGRNNNT-3'), which was experimenta

89 the cleavage efficiency of the Streptococcus pyogenes Cas9 protein based on expression using three di

90 es of the catalytically active Streptococcus pyogenes Cas9 R-loop that show the displaced DNA strand

91 tructures of AcrIIA2 or AcrIIA2b bound to S. pyogenes Cas9 reveal a mode of competitive inhibition of

92 s shows that in contrast to the type II-A S. pyogenes Cas9 that is widely used for genome engineering

93 sign rules and paired S. aureus Cas9 with S. pyogenes Cas9 to achieve dual targeting in a high fracti

94 s also blocked the widely used Streptococcus pyogenes Cas9 when assayed in Escherichia coli and human

95 ning a catalytically defective Streptococcus pyogenes Cas9, a cytidine deaminase, and an inhibitor of

96 Applied to Streptococcus pyogenes Cas9, a Hamiltonian metric obtained from coevol

97 ences to conditionally express Streptococcus pyogenes Cas9, and V. carteri U6 RNA gene regulatory seq

98 ng only the well-characterized Streptococcus pyogenes Cas9, by incorporating MS2 or PP7 RNA aptamers

99 M. tuberculosis, the existing Streptococcus pyogenes Cas9-based CRISPRi system is of limited utility

100 Streptococcus pyogenes Cas9-guide RNA (gRNA) was successfully applied

101 for target site recognition by Streptococcus pyogenes Cas9.

102 studies to date utilizing the Streptococcus pyogenes Cas9.

103 spacer-adjacent motif (PAM) of Streptococcus pyogenes Cas9.

104 exhibits greater specificity compared to S. pyogenes Cas9.

105 Streptococcus pyogenes causes 700 million human infections annually wo

106 Trueperella pyogenes causes tissue pathology in many mammals by secr

107 nd activity of SLO, DNase, and Streptococcus pyogenes cell envelope protease in vitro.

108 e form of the streptococcal CXC protease, S. pyogenes cell envelope proteinase, we developed a combin

109 pitopes of importance for phagocytosis of S. pyogenes cells are localized.

110 sequences of type emm1, emm28, and emm89 S. pyogenes clinical strains recovered from intercontinenta

111 Thus, human immune responses against S. pyogenes consist of a robust Th1 cellular memory respons

112 Using the Streptococcus pyogenes CRISPR-Cas adaptation machinery, we developed C

113 RISPR-Cas systems, such as the Streptococcus pyogenes CRISPR-Cas9 system, can be adapted such that Ca

114 re, we demonstrate that nuclease-inactive S. pyogenes CRISPR/Cas9 can bind RNA in a nucleic-acid-prog

115 GAS assay compared to that of Streptococcus pyogenes culture.

116 of promoters that cannot be activated by S. pyogenes dCas9.

117 system conserved in sequenced isolates of S. pyogenes Deletion of the QS system's transcriptional act

118 We analysed changes in S pyogenes emm genotypes, and notifications of scarlet fev

119 de- and tetracycline-resistant Streptococcus pyogenes emm12 isolates represent the majority of clinic

120 In conclusion, we have identified a novel S. pyogenes enzyme with 5'-nucleotidase activity and immune

121 niche and conduit to the bloodstream for S. pyogenes, explaining the phenomenon of occult bacteraemi

122 e cocultured ex vivo in the presence of an S pyogenes extract.

123 The "Big Papi" (paired aureus and pyogenes for interactions) approach described here will

124 ut not methicillin-resistant S. aureus or S. pyogenes from cellulitis tissue specimens.

125 examined the role of GacB, encoded in the S. pyogenes GAC gene cluster, in the GAC biosynthesis pathw

126 Importantly, the substitution of S. pyogenes gacB with the homologous gene from Streptococcu

127 of the human pathogen group A Streptococcus pyogenes (GAS) and subsequent hPg activation to the prot

128 M-proteins (M-Prt) in group A Streptococcus pyogenes (GAS) are surface-expressed virulence factors i

129 Infection by Group A Streptococcus pyogenes (GAS) is a leading cause of severe invasive dis

130 nophagocytosis enables group A Streptococcus pyogenes (GAS) to establish infection.

131 n genomic study of the group A Streptococcus pyogenes (GAS), a human pathogen with highly recombining

132 yogenes (gram-positive group A Streptococcus pyogenes [GAS]) recruit host single-chain human plasmino

133 fluorescence intensity of the Streptococcus pyogenes gave a signal that is up to 16.4 times higher t

134 that can detect intergenic regions of the S. pyogenes genome.

135 pyogenes genomes and 3407 sequence runs deposited in the

136 Virulent strains of Streptococcus pyogenes (gram-positive group A Streptococcus pyogenes [

137 Infections caused by Streptococcus pyogenes (group A Streptococcus [GAS]) are highly preval

138 al concern in the treatment of Streptococcus pyogenes (group A Streptococcus [GAS]) infections.

139 Streptococcus pyogenes (group A Streptococcus [GAS]) is a human pathog

140 The important human pathogen Streptococcus pyogenes (group A Streptococcus [GAS]) produces a hyalur

141 efflux in the pathogenesis of Streptococcus pyogenes (group A Streptococcus [GAS]), a human pathogen

142 Streptococcus pyogenes (group A Streptococcus [GAS]), a major human-sp

143 tive human-restricted pathogen Streptococcus pyogenes (Group A Streptococcus, GAS) has long focused o

144 The human-restricted pathogen Streptococcus pyogenes (Group A Streptococcus, GAS) is responsible for

145 ast Asian serotype M12 (emm12) Streptococcus pyogenes (group A Streptococcus, GAS) to cause scarlet f

146 As a strict human pathogen, Streptococcus pyogenes (group A Streptococcus, or GAS) causes a wide r

147 Streptococcus pyogenes (Group A streptococcus; GAS) is a human pathoge

148 pathogenic bacteria, including Streptococcus pyogenes (Group A Streptococcus; GAS), Streptococcus mut

149 editing using CRISPR/Cas9 from Streptococcus pyogenes has enabled rapid and accessible alteration of

150 atalytically, in the pili from Streptococcus pyogenes has highlighted the role that such cross-links

151 gy, and public health communities because S. pyogenes has remained universally susceptible to beta-la

152 Hypervirulent strains of S. pyogenes have evolved a plethora of virulence factors th

153 globulin G-degrading enzyme of Streptococcus pyogenes (IdeS) followed by chemical reduction.

154 -degrading enzyme derived from Streptococcus pyogenes (IdeS), an endopeptidase, cleaves human IgG int

155 tease, IgG-degrading enzyme of Streptococcus pyogenes (IdeS), cleaves the hinge region of heavy-chain

156 nzyme, IgG-degrading enzyme of Streptococcus pyogenes (IdeS), was shown to specifically cleave IgG mo

157 globulin G-degrading enzyme of Streptococcus pyogenes (IdeS), which is capable of digesting IgGs in o

158 gainst IgG-degrading enzyme of Streptococcus pyogenes (IdeS)- or pepsin-generated F(ab')2 fragments o

159 Staphylococcus epidermidis and Streptococcus pyogenes in a soft-tissue wound biofilm model.

160 he human adaptive immune response against S. pyogenes in both children and adults.

161 e T cells activated by epidermal cells and S pyogenes in patients with GP.

162 that promoted opsonophagocytic killing of S. pyogenes in vitro and provided passive immunity in vivo.

163 We found that FH6-7/Fc alleviated S. pyogenes-induced sepsis in a transgenic mouse model expr

164 S. pyogenes-induced Th17 formation depended on TGF-beta1 fr

165 I interferons produced during Streptococcus pyogenes infection are required to prevent inflammation-

166 naling protects the host against invasive S. pyogenes infection by restricting inflammation-driven da

167 unctive treatment for clinical Streptococcus pyogenes infection however, the protein targets of the r

168 ry testing for confirmation of Streptococcus pyogenes infection is required to prevent complications

169 d the finding that patients with invasive S. pyogenes infection respond with antibody production agai

170 oled human immunoglobulin during invasive S. pyogenes infection, and demonstrate a potential route to

171 l hallmarks of severe invasive Streptococcus pyogenes infection, sepsis.

172 -deficient mice are highly susceptible to S. pyogenes infection.

173 ion by MtsR are critical processes during S. pyogenes infection.

174 7 cell formation in mice after Streptococcus pyogenes infection.

175 axime, antibiotics commonly used to treat S. pyogenes infections, were reported.

176 ractive antivirulence drug target against S. pyogenes infections.

177 ssociated with severe invasive Streptococcus pyogenes infections.

178 expected elevation in invasive Streptococcus pyogenes infections.

179 o obtain new information about Streptococcus pyogenes intrahost genetic variation during invasive inf

180 adhesive is capable of killing Streptococcus pyogenes introduced subcutaneously at the bioadhesive's

181 We sequenced the genomes of 2,101 emm28 S. pyogenes invasive strains, from which we selected 492 ph

182 Streptococcus pyogenes is a human-restricted pathogen most often found

183 -guided Cas9 endonuclease from Streptococcus pyogenes is a single-turnover enzyme that displays a sta

184 protein secretion organelle in Streptococcus pyogenes is an anionic phospholipid-containing membrane

185 Streptococcus pyogenes is an important human pathogen that causes a wi

186 )-associated protein Cas9 from Streptococcus pyogenes is an RNA-guided DNA endonuclease with widespre

187 CRISPR-Cas9 from Streptococcus pyogenes is an RNA-guided DNA endonuclease, which has be

188 cellular level of c-di-AMP in Streptococcus pyogenes is predicted to be controlled by the synthase D

189 Type II-A SpCas9 protein from Streptococcus pyogenes is the most investigated and highly used enzyme

190 Group A Streptococcus (GAS; Streptococcus pyogenes) is a bacterial pathogen for which a commercial

191 he group A Streptococcus (GAS, Streptococcus pyogenes) is a Gram-positive bacterial pathogen from whi

192 he Group A Streptococcus (GAS, Streptococcus pyogenes) is a Gram-positive human pathogen that must ad

193 Group A Streptococcus (GAS, Streptococcus pyogenes) is a human-restricted pathogen with a capacity

194 nd 30 S. aureus, 15 S. pneumoniae, and 15 S. pyogenes isolates by disk diffusion (DD) methods.

195 Two near-identical clinical Streptococcus pyogenes isolates of emm subtype emm43.4 with a pbp2x mi

196 ns of people are infected with Streptococcus pyogenes, leading to an estimated 500,000 annual deaths

197 A dominant new emm1 S pyogenes lineage characterised by increased SpeA product

198 rol protein modules 6 and 7) that bind to S. pyogenes, linked to the Fc region of IgG (FH6-7/Fc).

199 lly inactive Cas9 (dCas9) from Streptococcus pyogenes loaded with single guide RNAs (sgRNAs) in mouse

200 us aureus (</=0.12 microg/mL), Streptococcus pyogenes (</=0.12 microg/mL), Streptococcus agalactiae (

201 S. pyogenes MHC class II-bound peptide-specific CD4(+) T ce

202 , Clostridioides difficile, or Streptococcus pyogenes, multiple highly conserved DNA MTases are also

203 Now S. pyogenes NAATs are being used with increasing frequency.

204 and Robin Patel of the Mayo Clinic, where S. pyogenes NAATs have been used for well over a decade wit

205 larger amounts of the secreted cytotoxins S. pyogenes NADase (SPN) and streptolysin O (SLO).

206 S. pyogenes NCTC 8198(T) and CCUG 4207(T) are derived from

207 combinant S5nA acted synergistically with S. pyogenes nuclease A to generate macrophage-toxic deoxyad

208 sis of an endoglycosidase from Streptococcus pyogenes of serotype M49 (Endo-S2) and the evaluation of

209 Streptococcus pyogenes, one of the most common human pathogens, secret

210 an be applied for specific agents such as S. pyogenes, or commercial multiplex NAATs for detection of

211 Streptococcus pyogenes, or group A Streptococcus (GAS), is a human bac

212 Streptococcus pyogenes, or group A Streptococcus (GAS), is a pathogen

213 h SPN and SLO contribute significantly to S. pyogenes pathogenesis in these virulence assays.

214 st sHIP suggest a role for the protein in S. pyogenes pathogenesis.

215 infection in a mouse model of Streptococcus pyogenes peritonitis.

216 Streptococcus pneumoniae, and Streptococcus pyogenes), positive percent agreement (PPA) and negative

217 In the human pathogen Streptococcus pyogenes, production of secreted virulence factor SpeB i

218 and recognised invasive potential of emm1 S pyogenes provide plausible explanation for the increased

219 Pyolysin (PLO) from Trueperella pyogenes provided a unique opportunity to explore cellul

220 Streptococcus pyogenes ranks among the main causes of mortality from b

221 pathogen carriage by phagocytes, we show S. pyogenes remain extracellular during transit, first in a

222 how SAgs contribute to the life cycle of S. pyogenes remain poorly understood.

223 n, the elucidation of GAC biosynthesis in S. pyogenes reported here enhances our understanding of how

224 nducted on streptolysin O from Streptococcus pyogenes revealed that this CDC also has glycan-binding

225 identify mutations in rgg2 of Streptococcus pyogenes (rgg2Sp ) that conferred pheromone-independent

226 nst most streptococcal species, including S. pyogenes, S. agalactiae, S. dysgalactiae, S. equi, S. mu

227 ogenic streptococci, including Streptococcus pyogenes, S. agalactiae, S. pneumoniae, and S. equi.

228 Streptococcus pyogenes secretes many toxins that facilitate human colo

229 he globally prominent pathogen Streptococcus pyogenes secretes potent immunomodulatory proteins known

230 s Streptococcus pneumoniae and Streptococcus pyogenes, SEER identifies relevant previously characteri

231 ntified across four contemporary invasive S. pyogenes serotypes (M1, M3, M12 and M89).

232 tions of saliva and plasma, and different S. pyogenes serotypes and their isogenic mutants, reveals h

233 The well-characterized Scl1 proteins of S. pyogenes show a dichotomous switch in ligand binding bet

234 e have developed CRISPR-RGR, a Streptococcus pyogenes (Sp)Cas9-based gene editing system for Plasmodi

235 ociated endonuclease Cas9 from Streptococcus pyogenes (spCas9) along with a single guide RNA (sgRNA)

236 target activities of Cas9 from Streptococcus pyogenes (SpCas9) and the SpCas9 variants xCas9 and SpCa

237 iated endonuclease (Cas)9 from Streptococcus pyogenes (SpCas9) can be used to edit single or multiple

238 ided CRISPR-Cas9 nuclease from Streptococcus pyogenes (SpCas9) has been widely repurposed for genome

239 rotein Cas9 from the bacterium Streptococcus pyogenes (SpCas9) in plasma samples by means of a bottom

240 eavage compared with wild-type Streptococcus pyogenes (SpCas9) in vivo.

241 ays demonstrate that Cas9 from Streptococcus pyogenes (SpCas9) is more active in creating double-stra

242 iated endonuclease (Cas)9 from Streptococcus pyogenes (SpCas9) is used to deplete VEGFR2 in vascular

243 of the commonly used Cas9 from Streptococcus pyogenes (SpCas9) limits its utility for basic research

244 st widely used is derived from Streptococcus pyogenes (SpCas9), with a complementary small guide RNA

245 nsactivator based on Cas9 from Streptococcus pyogenes (SpCas9).

246 phage-encoded endolysin, lyses Streptococcus pyogenes (Spy) on contact.

247 well-established ortholog from Streptococcus pyogenes (SpyCas9), and further engineer an increased ef

248 inities of Cas9 nucleases from Streptococcus pyogenes, Staphylococcus aureus, and Francisella novicid

249 ther virulent pathogens (e.g., Streptococcus pyogenes, Staphylococcus aureus, and potentially Haemoph

250 g bioinformatics analysis of the complete S. pyogenes strain SF370 genome, we have identified a novel

251 N and SLO in epidemic serotype M1 and M89 S. pyogenes strains is associated with rapid intercontinent

252 te, closed genome sequences of Streptococcus pyogenes strains NCTC 8198(T) and CCUG 4207(T), the type

253 ariation, we pooled DNA of 100 Streptococcus pyogenes strains of different emm types in two pools, ea

254 atants prepared from cultures of invasive S. pyogenes strains of varying serotypes in the stationary

255 uestion, we discovered that all sequenced S. pyogenes strains possess the genes for the malic enzyme

256 Recently, two related Streptococcus pyogenes strains with reduced susceptibility to ampicill

257 S. pyogenes strains with this type of polymorphism cause hu

258 aecalis, Enterococcus faecium, Streptococcus pyogenes, Streptococcus agalactiae, and Streptococcus pn

259 encoded by Bacillus subtilis, Streptococcus pyogenes, Streptococcus pneumoniae, Streptococcus mutans

260 canonical PAM preferences for Streptococcus pyogenes, Streptococcus thermophilus CRISPR3 (Sth3), and

261 r response to stress and for virulence in S. pyogenes, suggesting that its signaling pathway could be

262 The important human pathogen, Streptococcus pyogenes, synthesizes a key antigenic surface polymer, t

263 For many years, S. pyogenes testing algorithms used a rapid and specific gr

264 erized an intergenic VNTR polymorphism in S. pyogenes that affects toxin production and virulence.

265 based on a protein domain from Streptococcus pyogenes, that locks itself together via spontaneous iso

266 ion and increased virulence in Streptococcus pyogenes The nature of the polymorphism is a one-unit de

267 an exclusively human pathogen, Streptococcus pyogenes (the group A streptococcus [GAS]) has specifica

268 , including the human pathogen Streptococcus pyogenes(the group A Streptococcus[GAS]), we characteriz

269 sms, Staphylococcus aureus and Streptococcus pyogenes, the activity is dependent on prior lipoylation

270 ort that in the human pathogen Streptococcus pyogenes, the adaptive response to Mn limitation is cont

271 st the Gram-positive bacterium Streptococcus pyogenes This protein is composed of two domains of comp

272 egulatory system governing the ability of S. pyogenes to colonize the nasopharynx and provides knowle

273 linical settings, by a throat culture for S. pyogenes to increase the sensitivity of its detection.

274 The ability of Streptococcus pyogenes to infect different niches within its human hos

275 efield group A carbohydrate of Streptococcus pyogenes to study the effects of bacterial antigens on t

276 escued, demonstrating that the ability of S. pyogenes to utilize arginine was dispensable in the abse

277 n found that between 3.7 and 28.5% of the S. pyogenes transcripts were differentially expressed, depe

278 ylococcus aureus harboring the Streptococcus pyogenes type II-A CRISPR-Cas system.

279 r and invasive disease notifications, emm1 S pyogenes upper respiratory tract isolates increased sign

280 markably, these observations suggest that S. pyogenes uses SAgs to manipulate Vbeta-specific T cells

281 these challenges, the pathogen Streptococcus pyogenes utilizes the protein Cpa, a pilus tip-end adhes

282 nslocation (CMT), performed by Streptococcus pyogenes, utilizes the cholesterol-dependent cytolysin S

283 of reports of hypervirulent SpeB-negative S. pyogenes variants present during invasive infections.

284 SF370 genome, we have identified a novel S. pyogenes virulence factor, which we termed streptococcal

285 dependent manner, suggesting a role as an S. pyogenes virulence factor.

286 rophil extracellular traps, and modulates S. pyogenes virulence.

287 ureus and Listeria monocytogenes, DacA in S. pyogenes was not essential for growth in rich media.

288 reus was not found by culture or PCR, and S. pyogenes was not identified by any technique.

289 The Cas9 protein from Streptococcus pyogenes was pre-complexed with a single guide RNA targe

290 Type II-A SpCas9 from Streptococcus pyogenes was the first Cas9 nuclease used for genome edi

291 e pilus tip adhesin Spy0125 of Streptococcus pyogenes, we developed a single molecule assay to unambi

292 To investigate the role of c-di-AMP in S. pyogenes, we generated null mutants in each of these pro

293 neumoniae as reference, all species except S pyogenes were associated with significantly higher IE ri

294 epitope from the M protein of Streptococcus pyogenes, were designed by exchanging one amino acid at

295 t antibody complex specific to Streptococcus pyogenes, were volumetrically normalized according to th

296 It resembles the cel operon of Streptococcus pyogenes, which is implicated in the metabolism of cello

297 bacterial pathogens, including Streptococcus pyogenes, which utilizes the cholesterol-dependent cytol

298 te genome sequences of the type strain of S. pyogenes will effectively serve as valuable taxonomic an

299 surface of Gram-positive bacteria such as S. pyogenes will enable professional phagocytes to eliminat

300 Invasive strains of Streptococcus pyogenes with significantly reduced susceptibility to be